The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Anthony S. Wierzbicki

Lister Hospital

Stevenage

Hertfordshire

SG1 4AB

UK

[email]@kcl.ac.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Lister Hospital, Stevenage, Hertfordshire, SG1 4AB, UK. 2012
  • Department of Metabolic Medicine/Chemical Pathology, Guy's & St Thomas' NHS Trust, St Thomas Hospital, London, UK. 2011
  • St Thomas' Hospital, London, UK. 2001 - 2010
  • Department of Cardiology, Conquest (East Sussex) Hospital, Hastings, UK. 2010
  • Consultant Chemical Pathologist St Thomas' Hospital, Lambeth Palace Road London SE1 7EH UK, UK. 2010
  • Department of Chemical Pathology, St Thomas' Hospital, London, UK. 2000 - 2009
  • St Thomas' Hospital, Lambeth Palace Road, London, UK. 2007
  • King's College, London, UK. 2000

References

  1. Diagnosis and treatment of severe hypertriglyceridemia. Viljoen, A., Wierzbicki, A.S. Expert. Rev. Cardiovasc. Ther (2012) [Pubmed]
  2. The ezetimibe Jonah: the trials and tribulations of an unlucky drug. Wierzbicki, A.S. Int. J. Clin. Pract. (2011) [Pubmed]
  3. Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. Wierzbicki, A.S., Pendleton, S., McMahon, Z., Dar, A., Oben, J., Crook, M.A., Botha, A.J. Int. J. Clin. Pract. (2011) [Pubmed]
  4. HDL: who needs it? Wierzbicki, A.S. Int. J. Clin. Pract. (2011) [Pubmed]
  5. Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Wierzbicki, A.S. Curr. Opin. Lipidol. (2010) [Pubmed]
  6. The effect of fibrate-statin combination therapy on cardiovascular events: a retrospective cohort analysis. Wierzbicki, A.S., Morrell, J., Hemsley, D., McMahon, Z., Crook, M.A., Wray, R. Curr. Med. Res. Opin (2010) [Pubmed]
  7. Sodium-glucose co-transporter 2 inhibitors: from apple tree to 'Sweet Pee'. Hardman, T.C., Rutherford, P., Dubrey, S.W., Wierzbicki, A.S. Curr. Pharm. Des. (2010) [Pubmed]
  8. Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice. Wierzbicki, A.S., Viljoen, A. Drug. Saf (2010) [Pubmed]
  9. Interpreting clinical trials of diabetic dyslipidaemia: new insights. Wierzbicki, A.S. Diabetes. Obes. Metab (2009) [Pubmed]
  10. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Wierzbicki, A.S. Curr. Opin. Cardiol. (2009) [Pubmed]
  11. Future challenges for microsomal transport protein inhibitors. Wierzbicki, A.S., Hardman, T., Prince, W.T. Curr. Vasc. Pharmacol (2009) [Pubmed]
  12. SEARCHing for JUPITER: starry-eyed optimism is not warranted. Wierzbicki, A.S. Int. J. Clin. Pract. (2009) [Pubmed]
  13. Vascular risk screening: possible or too much, too soon?. Wierzbicki, A.S., Reynolds, T.M. Int. J. Clin. Pract. (2009) [Pubmed]
  14. Familial combined hyperlipidaemia: under - defined and under - diagnosed? Wierzbicki, A.S., Graham, C.A., Young, I.S., Nicholls, D.P. Curr. Vasc. Pharmacol (2008) [Pubmed]
  15. Waist circumference, metabolic syndrome and coronary artery disease in a Pakistani cohort. Wierzbicki, A.S., Nishtar, S., Lumb, P.J., Lambert-Hammill, M., Crook, M.A., Marber, M.S., Gill, J. Int. J. Cardiol. (2008) [Pubmed]
  16. Muddy waters: more stormy SEAS for ezetimibe. Wierzbicki, A.S. Int. J. Clin. Pract. (2008) [Pubmed]
  17. Insulin resistance phenotypes and coronary artery disease in a native Pakistani cohort. Wierzbicki, A.S., Nishtar, S., Lumb, P.J., Lambert-Hammill, M., Crook, M.A., Marber, M.S., Gill, J. Int. J. Clin. Pract. (2008) [Pubmed]
  18. Surrogate markers, atherosclerosis and cardiovascular disease prevention. Wierzbicki, A.S. Int. J. Clin. Pract. (2008) [Pubmed]
  19. A fishy business: omega-3 fatty acids and cardiovascular disease. Wierzbicki, A.S. Int. J. Clin. Pract. (2008) [Pubmed]
  20. Lipid-altering therapies and the progression of atherosclerotic disease. Wierzbicki, A.S. Cardiovasc. Intervent. Radiol (2007) [Pubmed]
  21. Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review. Wierzbicki, A.S. Biochem. Soc. Trans. (2007) [Pubmed]
  22. Homocysteine and cardiovascular disease: a review of the evidence. Wierzbicki, A.S. Diab. Vasc. Dis. Res (2007) [Pubmed]
  23. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Wierzbicki, A.S. Int. J. Clin. Pract. (2006) [Pubmed]
  24. Fibrates after the FIELD study: Some answers, more questions. Wierzbicki, A.S. Diab. Vasc. Dis. Res (2006) [Pubmed]
  25. Asymmetric dimethyl arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction. Wierzbicki, A.S., Solomon, H., Lumb, P.J., Lyttle, K., Lambert-Hammill, M., Jackson, G. Atherosclerosis (2006) [Pubmed]
  26. FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Wierzbicki, A.S. Int. J. Clin. Pract. (2006) [Pubmed]
  27. Statins and hypertension. Wierzbicki, A.S. J. Hum. Hypertens (2006) [Pubmed]
  28. Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?. Wierzbicki, A.S. Curr. Med. Res. Opin (2005) [Pubmed]
  29. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Wierzbicki, A.S., Doherty, E., Lumb, P.J., Chik, G., Crook, M.A. Curr. Med. Res. Opin (2005) [Pubmed]
  30. Metabolic syndrome and risk of coronary heart disease in a Pakistani cohort. Wierzbicki, A.S., Nishtar, S., Lumb, P.J., Lambert-Hammill, M., Turner, C.N., Crook, M.A., Marber, M.S., Gill, J. Heart (2005) [Pubmed]
  31. Impaired renal function and atherosclerosis in a Pakistani cohort. Wierzbicki, A.S., Nishtar, S., Lumb, P.J., Lambert-Hammill, M., Crook, M.A., Marber, M.S., Gill, J. Curr. Med. Res. Opin (2005) [Pubmed]
  32. Cardiovascular risk factors and endothelial dysfunction. Wierzbicki, A.S., Chowienczyk, P.J., Cockcroft, J.R., Brett, S.E., Watts, G.F., Jenkins, B.S., Ritter, J.M. Clin. Sci. (2004) [Pubmed]
  33. Lipid-lowering therapies in development. Wierzbicki, A.S. Expert. Opin. Investig. Drugs (2004) [Pubmed]
  34. Lipid-altering agents: the future. Wierzbicki, A.S. Int. J. Clin. Pract. (2004) [Pubmed]
  35. Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum disease. Wierzbicki, A.S., Mayne, P.D., Lloyd, M.D., Burston, D., Mei, G., Sidey, M.C., Feher, M.D., Gibberd, F.B. J. Lipid Res. (2003) [Pubmed]
  36. Statin-fibrate combination: therapy for hyperlipidemia: a review. Wierzbicki, A.S., Mikhailidis, D.P., Wray, R., Schacter, M., Cramb, R., Simpson, W.G., Byrne, C.B. Curr. Med. Res. Opin (2003) [Pubmed]
  37. New lipid-lowering agents. Wierzbicki, A.S. Expert. Opin. Emerg. Drugs (2003) [Pubmed]
  38. Usefulness of Orlistat in the treatment of severe hypertriglyceridemia. Wierzbicki, A.S., Reynolds, T.M., Crook, M.A. Am. J. Cardiol. (2002) [Pubmed]
  39. Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. Wierzbicki, A.S., Lloyd, M.D., Schofield, C.J., Feher, M.D., Gibberd, F.B. J. Neurochem. (2002) [Pubmed]
  40. Beyond LDL-C--the importance of raising HDL-C. Wierzbicki, A.S., Mikhailidis, D.P. Curr. Med. Res. Opin (2002) [Pubmed]
  41. Total research productivity in a pathology discipline. Wierzbicki, A.S., Reynolds, T.M. J. Clin. Pathol. (2002) [Pubmed]
  42. The apolipoprotein E2 allele modulates activity and maximal velocity of the sodium-lithium countertransporter. Wierzbicki, A.S., Hardman, T.C., Cheung, J., Lambert-Hammill, M., Patel, S., Morrish, Z., Lumb, P.J., Lant, A.F. Am. J. Hypertens. (2002) [Pubmed]
  43. Stroke in systemic lupus erythematosus. Wierzbicki, A.S. Expert. Rev. Neurother (2002) [Pubmed]
  44. Relation between sodium-lithium countertransport and hypertriglyceridemia in type V hyperlipidemia. Wierzbicki, A.S., Hardman, T.C., Cheung, J., Patel, M., Smallberger, S., Lumb, P.J., Lant, A.F. Am. J. Hypertens. (2001) [Pubmed]
  45. Lipid-lowering drugs in lupus: an unexplored therapeutic intervention. Wierzbicki, A.S. Lupus (2001) [Pubmed]
  46. Atorvastatin. Wierzbicki, A.S. Expert. Opin. Pharmacother (2001) [Pubmed]
  47. Very low-density lipoprotein apolipoprotein B-100 turnover in glycogen storage disease type Ia (von Gierke disease). Wierzbicki, A.S., Watt, G.F., Lynas, J., Winder, A.F., Wray, R. J. Inherit. Metab. Dis. (2001) [Pubmed]
  48. Drug treatment of combined hyperlipidemia. Wierzbicki, A.S., Mikhailidis, D.P., Wray, R. Am. J. Cardiovasc. Drugs (2001) [Pubmed]
  49. A comparison of algorithms for initiation of lipid lowering therapy in primary prevention of coronary heart disease. Wierzbicki, A.S., Reynolds, T.M., Gill, K., Alg, S., Crook, M.A. J. Cardiovasc. Risk (2000) [Pubmed]
  50. Identification of genetic heterogeneity in Refsum's disease. Wierzbicki, A.S., Mitchell, J., Lambert-Hammill, M., Hancock, M., Greenwood, J., Sidey, M.C., de Belleroche, J., Gibberd, F.B. Eur. J. Hum. Genet. (2000) [Pubmed]
  51. Effects of lipids in patients with familial hypercholesterolaemia on the kinetics of the sodium-lithium countertransporter. Wierzbicki, A.S., Hardman, T.C., Cheung, J., Lambert-Hammill, M., Patel, S., Morrish, Z., Lumb, P.J., Lant, A.F. J. Hum. Hypertens (2000) [Pubmed]
  52. High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia. Wierzbicki, A.S., Lumb, P.J., Chik, G., Crook, M.A. Am. J. Cardiol. (2000) [Pubmed]
  53. Differing relationships of methylene tetrahydrofolate reductase genotypes with cardiovascular risk in familial and polygenic hypercholesterolaemia. Wierzbicki, A.S., Lambert-Hammill, M., Junadi, E., Lumb, P.J., Crook, M.A. J. Cardiovasc. Risk (2000) [Pubmed]
 
WikiGenes - Universities